Ligand Pharmaceuticals is putting serious money behind AvenCell Therapeutics. The company has agreed to a deal worth up to $47 million to help speed up new CAR T therapies for some of the hardest cancer cases—relapsed or refractory acute myeloid leukemia (AML) and B cell cancers.
Oppenheimer reiterated an Outperform rating and a $334 price target on Ligand following the AvenCell deal, highlighting the structured financing and royalty exposure as key factors.
AvenCell stands out in the crowded cell therapy field because of its own platform. The company combines CRISPR-edited allogeneic CAR T technology with a switchable CAR system. This setup is meant to give doctors more control over CAR T cell activity. The hope is to cut down on side effects and treat more diseases. The lead drug, AVC-201, is already in a Phase 1b expansion trial for relapsed or refractory AML. AVC-203 is moving through Phase 1a for B cell cancers, according to Ligand’s investor updates.
Ligand CEO Todd Davis spelled out the company’s thinking: “AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity.” Davis pointed to early clinical data from AVC-201 as a sign the platform could reach across blood cancers and autoimmune diseases.
Independent clinical-trial tracking shows that AVC-203 is being evaluated in a recruiting Phase 1/2 trial with a planned enrollment of 178 participants at sites in the United States and Germany, indicating a more advanced development stage than previously summarized.
Ligand’s investment isn’t just about royalties. The company has also set aside up to $6 million for Series C equity in AvenCell. More details on that will come later. Hogan Lovells Cadwalader handled legal work for Ligand.
There’s a lot riding on this deal for both patients and investors. The milestone-based structure means AvenCell has to show real clinical progress to unlock the full funding. Ligand’s strategy is to build a broad royalty portfolio, aiming for steady revenue from a wide mix of biopharma assets. This approach has made Ligand one of the biggest royalty aggregators in the industry, with stakes in over 200 development and commercial stage assets.
Switchable, off-the-shelf CAR T therapies hold promise, but the risks are real. Both companies admit the clinical data are still early. Future funding depends on hitting key milestones. There are still big hurdles in manufacturing, regulation, and competition. There’s no guarantee early results will turn into commercial success. These challenges are familiar to others in the CAR T field, as seen in reported earlier efforts to bring CAR T to new cancer types.
Ligand is making a calculated bet on the future of controllable, off-the-shelf cell therapies. By tying its returns to AvenCell’s clinical and commercial progress, Ligand is putting its money on real-world results. If AvenCell’s platform delivers, this partnership could change the outlook for patients with relapsed AML and B cell cancers—diseases where current treatments often fall short. The deal shows how capital, technology, and clinical ambition are coming together to push cell therapy forward, with both risk and reward depending on the next round of clinical data.
